Global Angiotensin Receptor Blockers (ARBs) Market Trends: Regional Breakdowns and Strategic Insights
Discover trends, market shifts, and competitive outlooks for the angiotensin receptor blockers (arbs) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
#What is the Anticipated CAGR of the Angiotensin Receptor Blockers (ARBs) Market, and What Factors Will Drive It?
In recent times, there’s been a steady rise in the market size of angiotensin receptor blockers (ARBs). Its growth is predicted to increase from $8.51 billion in 2024 to $8.87 billion in 2025, indicating a compound annual growth rate (CAGR) of 4.1%. The historical growth of this market can be traced back to the epidemic of hypertension, efficacy in clinical trials, high burden of cardiovascular diseases, protection of renal health, clinical guidelines, the trend of using ARBs as the first line of treatment, and its cost-effectiveness.
The market for angiotensin receptor blockers (ARBs) is anticipated to experience consistent expansion in the coming years, reaching a value of $10.76 billion in 2029, with a compound annual growth rate (CAGR) of 5.0%. This growth forecast can be attributed to several factors including the adoption of precision medicine, a focus on combination therapies, global market expansion, the use of biomarker-based treatment methods, government initiatives, and heightened hypertension awareness. The forecast period is also expected to see trends such as the adoption of telemedicine, increased investments in research and development, competition from generic brands and patent expirations, the use of digital health solutions to increase medication adherence, and competition from biosimilars.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Angiotensin Receptor Blockers (ARBs) Market?
The growth of the angiotensin receptor blockers market is anticipated to be driven by the escalating occurrence of cardiovascular diseases. Any condition that impacts the heart or blood vessels is defined as cardiovascular disease (CVD). Often, it’s linked with the manifestation of fatty accumulations within the arteries (atherosclerosis) and an escalated probability of blood clots. Angiotensin receptor blockers are known to decrease blood pressure and enhance the heart’s ability to circulate blood by aiding in the relaxation of veins and arteries. This can potentially reduce the cardiovascular disease risk. For example, the American College of Cardiology, a professional medical organization based in the US, predicted in August 2022, that there will be a significant increase in cardiovascular risk factors and disease in the United States by 2060. Therefore, the mounting prevalence of cardiovascular diseases is fueling the expansion of the angiotensin receptor blockers market.
Which Key Market Segments Comprise the Angiotensin Receptor Blockers (ARBs) Market and Drive Its Revenue Growth?
The angiotensin receptor blockers (ARBs) market covered in this report is segmented –
1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Valsartan: Tablets, Capsules, Injectable Forms
2) By Telmisartan: Tablets, Capsules
3) By Losartan: Tablets, Oral Solution
4) By Irbesartan: Tablets, Oral Solution
5) By Azilsartan: Tablets
6) By Olmesartan: Tablets, Oral Suspension
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp
Which Areas Are Leading Regions in the Angiotensin Receptor Blockers (ARBs) Market Expansion Across the Globe?
North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Strategic Trends Steering theAngiotensin Receptor Blockers (ARBs) Market Direction?
Leading firms within the angiotensin receptor blocker market are pursuing the creation of sophisticated offerings such as angiotensin receptor neprilysin inhibitors to expand therapeutic resources and improve patient outcomes with cardiovascular diseases. Angiotensin receptor neprilysin inhibitors (ARNIs) serve as a medication class for managing heart failure. Take, for instance, Glenmark Pharmaceuticals, a pharmaceutical company based in India, which, in January 2023, initiated the distribution of sacubitril + valsartan tablets. These tablets are designed specifically to tackle heart failure, particularly heart failure with reduced ejection fraction (HFrEF). This combined medication belongs to the ARNI (angiotensin receptor neprilysin inhibitors) category. Sacubitril boosts the natriuretic peptide (NP) system to relieve fluid overload and facilitate blood vessel expansion. Simultaneously, valsartan inhibits the renin-angiotensin system (RAS), reducing blood pressure and lightening the load on the heart. Collectively, these drugs alleviate symptoms of heart failure, curtail the probability of cardiovascular death, and diminish the likelihood of heart failure hospital admissions. They are sold under the brand name Sacu V.
View the full report here:
How Is the Angiotensin Receptor Blockers (ARBs) Market Conceptually Defined?
Angiotensin receptor blockers (ARBs) are medications that dilate (widen) blood vessels and are used to treat conditions such as high blood pressure (hypertension), heart failure, and kidney disease in people with diabetes. Angiotensin is a chemical in the body that causes blood vessels to constrict. This constriction can raise the blood pressure and make the heart work harder.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8943
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
